Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind placebo controlled study to evaluate the safety of STP705 administered as subcutaneous injection into healthy volunteers with either single dose escalation or multiple dose escalation

Next Previous
X
Search
Trial Profile

A randomized, double-blind placebo controlled study to evaluate the safety of STP705 administered as subcutaneous injection into healthy volunteers with either single dose escalation or multiple dose escalation

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 03 May 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STP 705 (Primary)
  • Indications Hypertrophic scars
  • Focus Adverse reactions

    • Most Recent Events

    • 03 May 2017 New trial record
    • 01 May 2017 Suzhou Sirnaomics Pharmaceuticals has received an approval from China Food and Drug Administration (CFDA) for an IND application of STP705 (Cotsiranib) for the treatment of hypertrophic scars.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top